JP2008509086A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008509086A5 JP2008509086A5 JP2007515288A JP2007515288A JP2008509086A5 JP 2008509086 A5 JP2008509086 A5 JP 2008509086A5 JP 2007515288 A JP2007515288 A JP 2007515288A JP 2007515288 A JP2007515288 A JP 2007515288A JP 2008509086 A5 JP2008509086 A5 JP 2008509086A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- ligand
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57389604P | 2004-05-25 | 2004-05-25 | |
| US60/573,896 | 2004-05-25 | ||
| PCT/US2005/018322 WO2005116077A2 (en) | 2004-05-25 | 2005-05-25 | LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008509086A JP2008509086A (ja) | 2008-03-27 |
| JP2008509086A5 true JP2008509086A5 (enExample) | 2008-07-10 |
| JP4890449B2 JP4890449B2 (ja) | 2012-03-07 |
Family
ID=35451457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007515288A Expired - Lifetime JP4890449B2 (ja) | 2004-05-25 | 2005-05-25 | 下流ｕＰＡＲ相互作用を阻害するウロキナーゼ型プラスミノーゲン活性化因子（ｕＰＡ）とそのレセプター（ｕＰＡＲ）との複合体に結合するリガンド：診断または治療における同定および使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8101726B2 (enExample) |
| EP (1) | EP1765397B1 (enExample) |
| JP (1) | JP4890449B2 (enExample) |
| KR (1) | KR20070047246A (enExample) |
| CN (1) | CN101022830A (enExample) |
| AU (1) | AU2005248400A1 (enExample) |
| CA (1) | CA2568428C (enExample) |
| DK (1) | DK1765397T3 (enExample) |
| ES (1) | ES2398221T3 (enExample) |
| IL (1) | IL179565A0 (enExample) |
| MX (1) | MXPA06013709A (enExample) |
| PL (1) | PL1765397T3 (enExample) |
| PT (1) | PT1765397E (enExample) |
| RU (1) | RU2006145905A (enExample) |
| WO (1) | WO2005116077A2 (enExample) |
| ZA (1) | ZA200610578B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007109742A2 (en) * | 2006-03-21 | 2007-09-27 | Weaver David T | Methods for humanizing antibodies and humanized antibodies made thereby |
| CN1919874B (zh) * | 2006-09-18 | 2010-09-08 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途 |
| US8105602B2 (en) * | 2006-12-08 | 2012-01-31 | Tactic Pharma, Llc | Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof |
| US8815519B2 (en) | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2730282A1 (en) * | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| EP2352503B1 (en) * | 2008-11-06 | 2017-07-19 | University of Miami | Role of soluble upar in the pathogenesis of proteinuric kidney disease |
| EP3187877A1 (en) | 2009-09-25 | 2017-07-05 | XOMA Technology Ltd. | Screening methods |
| BR112013016107A2 (pt) | 2010-12-22 | 2017-04-04 | Ifom Fond Inst Firc Di Oncologia Molecolare | molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar |
| CA3027071A1 (en) | 2011-01-14 | 2013-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| TWI700093B (zh) | 2011-03-16 | 2020-08-01 | 法商賽諾菲公司 | 雙重ｖ區類抗體蛋白質之用途 |
| US9867923B2 (en) | 2011-05-09 | 2018-01-16 | University Of Miami | Reducing soluble urokinase receptor in the circulation |
| CN103930128A (zh) | 2011-08-05 | 2014-07-16 | 意大利癌症研究基金会分子肿瘤学研究所(Ifom) | 组成型活性uPAR变体及其在抑制性抗体的生成与分离中的应用 |
| KR102268883B1 (ko) * | 2013-03-15 | 2021-06-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해 |
| CN105368859B (zh) * | 2015-11-25 | 2019-10-18 | 王任直 | 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用 |
| US10681506B1 (en) | 2018-04-19 | 2020-06-09 | Tango Tango, Inc. | System and method for push-to-talk over cellular integration with software defined radio |
| US10959062B1 (en) | 2018-04-19 | 2021-03-23 | Tango Tango, Inc. | System and method for push-to-talk over cellular integration with software defined radio |
| WO2020055812A1 (en) | 2018-09-10 | 2020-03-19 | Lung Therapeutics, Inc. | Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis |
| CA3114176A1 (en) * | 2018-09-28 | 2020-04-02 | Jochen Reiser | Supar and prediction and treatment of acute kidney injury |
| EP4051714A4 (en) * | 2019-10-28 | 2023-11-22 | Monash University | ANTIBODIES FOR BINDING PLASMIN |
| CN115867570A (zh) * | 2020-06-15 | 2023-03-28 | 莫诺帕医疗公司 | 精确放射免疫治疗靶向尿激酶纤溶酶原激活剂受体（uPAR）以治疗严重COVID-19疾病 |
| WO2022204267A1 (en) | 2021-03-24 | 2022-09-29 | Alkermes, Inc. | Upar antibodies and fusion proteins with the same |
| EP4341265A4 (en) * | 2021-05-21 | 2025-07-23 | Northstar Medical Tech Llc | TRIVALENT RADIOISTOPE BIO-TARGETED RADIOPHARMACEUTICAL, METHODS OF PREPARATION AND USE |
| CN117715648A (zh) * | 2021-06-11 | 2024-03-15 | 纪念斯隆-凯特琳癌症中心 | 靶向uPAR的抗原识别受体和其用途 |
| CA3246325A1 (en) * | 2022-03-24 | 2023-09-28 | The United States Government As Representative By The Department Of Veterans Affairs | Urokinase-type plasminogen activator receptor-binding peptides and methods of use |
| EP4610269A1 (en) | 2024-02-29 | 2025-09-03 | 3B Pharmaceuticals GmbH | Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use |
| WO2025207781A1 (en) | 2024-03-26 | 2025-10-02 | Monopar Therapeutics Inc. | Antibody radioisotope constructs |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532132A (en) * | 1993-09-28 | 1996-07-02 | President And Fellows Of Harvard University | Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor |
| DE10117381A1 (de) * | 2001-04-06 | 2002-10-10 | Wilex Biotechnology Gmbh | Herstellung polyklonaler, monospezifischer Antikörper gegen die uPAR-Varianten del4, del5 und del4+5 sowie deren Verwendung für diagnostische und therapeutische Zwecke |
| WO2003079974A2 (en) * | 2002-03-18 | 2003-10-02 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Integrin ligand |
| US8105602B2 (en) * | 2006-12-08 | 2012-01-31 | Tactic Pharma, Llc | Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof |
-
2005
- 2005-05-25 KR KR1020067027198A patent/KR20070047246A/ko not_active Withdrawn
- 2005-05-25 US US11/597,689 patent/US8101726B2/en active Active
- 2005-05-25 CN CNA2005800249140A patent/CN101022830A/zh active Pending
- 2005-05-25 PL PL05754219T patent/PL1765397T3/pl unknown
- 2005-05-25 RU RU2006145905/13A patent/RU2006145905A/ru not_active Application Discontinuation
- 2005-05-25 PT PT57542193T patent/PT1765397E/pt unknown
- 2005-05-25 AU AU2005248400A patent/AU2005248400A1/en not_active Abandoned
- 2005-05-25 EP EP05754219A patent/EP1765397B1/en not_active Expired - Lifetime
- 2005-05-25 JP JP2007515288A patent/JP4890449B2/ja not_active Expired - Lifetime
- 2005-05-25 MX MXPA06013709A patent/MXPA06013709A/es active IP Right Grant
- 2005-05-25 DK DK05754219.3T patent/DK1765397T3/da active
- 2005-05-25 CA CA2568428A patent/CA2568428C/en not_active Expired - Lifetime
- 2005-05-25 WO PCT/US2005/018322 patent/WO2005116077A2/en not_active Ceased
- 2005-05-25 ES ES05754219T patent/ES2398221T3/es not_active Expired - Lifetime
- 2005-05-25 ZA ZA200610578A patent/ZA200610578B/xx unknown
-
2006
- 2006-11-23 IL IL179565A patent/IL179565A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008509086A5 (enExample) | ||
| JP7165217B2 (ja) | 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法 | |
| JP7014706B2 (ja) | 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法 | |
| IL290412B2 (en) | New monoclonal antibodies to cd47 and their uses | |
| RU2006145905A (ru) | Лиганды, связывающие комплекс активатора плазминогена урокиназного типа (upa) и его рецептора (upar), которые ингибируют последующие взаимодействия upar: идентификация и использование в диагностике или терапии | |
| JP2009517057A5 (enExample) | ||
| JP2019534034A5 (enExample) | ||
| JP2005538701A5 (enExample) | ||
| IL255416B1 (en) | Anti – cd71 antibodies, activatable anti – cd71 antibodies compositions comprising same and uses thereof | |
| JP2013506428A5 (enExample) | ||
| US8735554B2 (en) | Reagents, methods, and systems for detecting methicillin-resistant Staphylococcus | |
| RU2008146922A (ru) | Антитела, связывающиеся с внеклеточным доменом тирозинкиназного рецептора (alk) | |
| WO2011083088A2 (en) | Methods for treating colorectal cancer | |
| EP3762420A1 (en) | Activatable cd147 antibodies and methods of making and use thereof | |
| JP2010523096A5 (enExample) | ||
| JP2010501164A5 (enExample) | ||
| JP2013531655A5 (enExample) | ||
| CN102143978A (zh) | 抗p2x7肽和表位 | |
| EP3085387A1 (en) | Sparc binding antibodies and uses thereof | |
| JP2005535562A5 (enExample) | ||
| WO2022143552A1 (zh) | Pd-1结合分子及其应用 | |
| RU2016129526A (ru) | Антитело, выделенная нуклеиновая кислота, выделенный паратоп антитела, выделенный конформационный эпитоп, связывающая молекула, иммуноген, фармацевтический и диагностический препараты, лекарственная форма вакцины, способ лечения больного, подверженного риску или страдающего от инфекции Staphylococcus aureus, способ диагностики обнаружения инфекций Staphylococcus aureus и способ скрининга или анализа для определения связующего | |
| EP2984108B1 (en) | Anti-s100a7 antibodies for the treatment and diagnosis of cancer | |
| JP2009544574A5 (enExample) | ||
| WO2023051618A1 (zh) | Ctla-4结合分子及其应用 |